The 0.4 milligram figure is quoted everywhere and read carefully almost nowhere. Two words in the statutory text determine what you can actually build, and both are regularly dropped.
The exact wording
From Section 781 of Public Law 119-37, a final hemp-derived cannabinoid product is excluded from the hemp definition if it contains:
“greater than 0.4 milligrams combined total per container of… total tetrahydrocannabinols (including tetrahydrocannabinolic acid); and any other cannabinoids that have similar effects (or are marketed to have similar effects) on humans or animals as a tetrahydrocannabinol (as determined by the Secretary of Health and Human Services).”
The two words are combined and container.
Combined: your cannabinoid budget is shared
The limit is not 0.4 mg of THC with separate allowances elsewhere. It is 0.4 mg total across THC, THCA and any other cannabinoid HHS determines to have similar effects.
Three consequences for formulation.
Substitution does not create headroom. Replacing THC with another intoxicating cannabinoid moves the number within the same budget rather than out of it.
Full-spectrum and broad-spectrum inputs consume budget you may not have counted. Minor cannabinoids that were never on your spec sheet can matter here, which means a narrow THC-only panel may not tell you whether a product complies.
Marketing language is evidence. The clause captures cannabinoids “marketed to have similar effects”. How you describe a product forms part of the assessment of what it is, which is an unusual and deliberate piece of drafting.
Container: pack architecture is now a compliance decision
The measurement attaches to the container, meaning the innermost retail packaging, rather than to the serving.
Practically, the same formula in two pack sizes produces two different compliance answers. A single-serve unit and a thirty-count jar are assessed on their totals, so the jar carries thirty times the exposure.
Two design routes follow, and only one of them is real. Reducing pack count moves the number, but not far enough to matter when the target is 0.4 mg for the whole container. Reducing per-unit content is the genuine route, and it takes you to a dose that is not doing what your current product does.
That is the honest read. For intoxicating products this is not a formulation constraint, it is a different product category. Say so internally, early, rather than spending a quarter proving it.
What you can actually build
Genuine low-dose products under the combined cap, built from cannabinoids the plant produced rather than a reactor.
CBD-forward products, with the caveat that the combined total still applies. Isolate-based formulas have more headroom than full-spectrum ones here, which is a real trade-off against the sensory and positioning reasons brands chose full-spectrum in the first place.
And non-cannabinoid products, where the constraint disappears entirely because none of these clauses reach terpenes or other non-cannabinoid constituents.
The formulation consequence nobody budgets for
If a product loses its cannabinoid payload, the aromatic profile stops being a supporting element and becomes the whole proposition.
That raises the specification rather than lowering it. An approximate profile assembled to suggest a cultivar reads as generic when nothing else is present, which is exactly the distinction we set out in real cultivars versus blended approximations. It also puts weight on batch consistency and on stability, because a profile that drifts over shelf life has nothing covering for it.
Practical next steps
Calculate combined cannabinoid content per container for every SKU and pack size. Widen your analytical panel beyond THC. Review product claims and marketing copy against the similar-effects clause. Then decide what is genuinely reformulable and what is not.
If the answer for a given SKU is that it becomes a non-intoxicating product, the sourcing question changes with it, and custom formulation partners become more relevant than catalogue purchasing.
About this brief
Written 17 July 2026 and checked against the statute and the Federal Register rather than against secondary coverage. This is a summary for commercial planning, not legal advice. Where the answer depends on your product format, your state or your licence position, take the specific question to your own counsel.
